CRIS Current Research Information System

ARDIZZONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.889
AS - Asia 17.924
EU - Europa 11.048
SA - Sud America 1.095
Continente sconosciuto - Info sul continente non disponibili 1.029
AF - Africa 1.006
OC - Oceania 34
Totale 51.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.507
SG - Singapore 4.894
VN - Vietnam 4.779
CN - Cina 4.431
IT - Italia 2.679
GB - Regno Unito 2.568
DE - Germania 1.368
HK - Hong Kong 1.194
IN - India 895
SE - Svezia 888
FR - Francia 820
BR - Brasile 769
RU - Federazione Russa 627
IE - Irlanda 429
NL - Olanda 407
JP - Giappone 363
ZA - Sudafrica 304
BD - Bangladesh 298
KR - Corea 292
FI - Finlandia 269
TG - Togo 242
EE - Estonia 212
CA - Canada 197
CH - Svizzera 194
CI - Costa d'Avorio 181
UA - Ucraina 176
AR - Argentina 125
SC - Seychelles 116
ID - Indonesia 104
MX - Messico 91
JO - Giordania 90
TH - Thailandia 85
PH - Filippine 84
AT - Austria 72
BG - Bulgaria 71
EC - Ecuador 66
TR - Turchia 64
IQ - Iraq 61
TW - Taiwan 57
PL - Polonia 54
NG - Nigeria 48
ES - Italia 44
PK - Pakistan 42
CO - Colombia 40
BE - Belgio 38
SA - Arabia Saudita 35
UZ - Uzbekistan 32
AU - Australia 30
VE - Venezuela 27
PY - Paraguay 24
DZ - Algeria 22
EG - Egitto 22
CL - Cile 21
GR - Grecia 19
JM - Giamaica 19
LB - Libano 19
TN - Tunisia 19
LT - Lituania 17
MY - Malesia 17
CR - Costa Rica 16
MA - Marocco 14
PT - Portogallo 13
HR - Croazia 12
IL - Israele 12
IR - Iran 11
OM - Oman 10
CZ - Repubblica Ceca 9
KE - Kenya 9
PE - Perù 9
HN - Honduras 8
HU - Ungheria 8
RO - Romania 8
AZ - Azerbaigian 7
ET - Etiopia 7
GT - Guatemala 7
KG - Kirghizistan 7
KZ - Kazakistan 7
NP - Nepal 7
UY - Uruguay 7
AL - Albania 6
BY - Bielorussia 6
MK - Macedonia 6
NI - Nicaragua 6
PA - Panama 6
BO - Bolivia 5
GP - Guadalupe 5
KW - Kuwait 5
SK - Slovacchia (Repubblica Slovacca) 5
AE - Emirati Arabi Uniti 4
BB - Barbados 4
LV - Lettonia 4
MU - Mauritius 4
PR - Porto Rico 4
RS - Serbia 4
SN - Senegal 4
SV - El Salvador 4
BS - Bahamas 3
EU - Europa 3
GA - Gabon 3
MD - Moldavia 3
Totale 49.940
Salva come PNG Salva come JPEG
Città #
Singapore 3.477
Southend 2.227
Ashburn 1.959
Fairfield 1.891
Hong Kong 1.131
San Jose 1.030
Houston 1.020
Ho Chi Minh City 1.003
Chandler 966
Woodbridge 945
Hanoi 882
Seattle 822
Wilmington 800
Cambridge 686
Santa Clara 686
Dong Ket 614
Princeton 581
Beijing 580
Bologna 574
Hefei 560
Boardman 510
Council Bluffs 475
Dublin 427
Ann Arbor 411
Lauterbourg 363
Tokyo 306
Los Angeles 287
Shanghai 283
Seoul 254
Lomé 242
Westminster 228
Nanjing 221
Dallas 212
Helsinki 212
New York 212
Milan 198
Abidjan 181
Padova 170
Buffalo 149
San Diego 147
Bern 141
Redondo Beach 134
Da Nang 126
Berlin 125
São Paulo 122
Redmond 119
Shenyang 119
Jinan 118
Haiphong 116
Medford 109
Saint Petersburg 107
Tianjin 106
Frankfurt am Main 100
Rome 97
Turin 95
Changsha 91
Guangzhou 91
Amman 86
Chicago 85
Nanchang 75
Bengaluru 65
Visakhapatnam 65
Hải Dương 64
Munich 62
Sofia 61
Hebei 60
Johannesburg 60
Shenzhen 60
Falls Church 59
Zhengzhou 59
London 57
Phoenix 57
Nuremberg 54
Biên Hòa 52
Can Tho 52
Florence 52
Jiaxing 52
The Dalles 51
Bremen 48
Jakarta 48
Hangzhou 47
Montreal 47
Orem 47
Abeokuta 45
Redwood City 45
Des Moines 44
Bühl 43
Dearborn 43
Atlanta 42
Norwalk 42
Vienna 42
Mexico City 40
Naples 39
Quận Bình Thạnh 39
Brussels 37
Toronto 37
Modena 36
Ha Long 35
Ninh Bình 34
Bangkok 33
Totale 32.039
Salva come PNG Salva come JPEG
Nome #
Transdermal Fentanyl in Patients with Cachexia-A Scoping Review 646
IFN-γ and CD38 in Hyperprogressive Cancer Development 442
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 379
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 343
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 296
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 291
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 290
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 277
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 276
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 273
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 257
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 256
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 256
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 247
Next-generation technologies in predictive molecular pathology of lung cancers 247
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 245
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 239
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) 239
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 238
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 232
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 225
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study 223
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 222
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 222
Circulating tumor cells in genitourinary tumors 222
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy 216
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 215
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 213
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 212
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 211
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 209
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 208
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 206
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 204
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 204
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 201
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting 200
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 196
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) 194
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 193
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 193
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 191
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 190
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC 189
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 188
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 188
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 188
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 187
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer 185
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 185
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 185
Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response 184
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 183
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma 181
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 181
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 180
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer 180
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 180
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 178
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 177
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 176
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 176
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 175
Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature 174
Immune-mediated cholangitis: is it always nivolumab’s fault? 173
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins 173
Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer 172
Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial 172
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer 170
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 168
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 168
SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor 167
Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling 167
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 166
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 165
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials 163
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 163
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab 163
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 163
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 162
Chemotherapy treatment in malignant pleural mesothelioma: A difficult history 162
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 162
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 162
Thoracic myopericytoma in an older adult, rare but possible: A case report 161
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study 161
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program 161
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study 160
Immune checkpoint inhibitors for metastatic bladder cancer 160
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 160
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 160
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 159
ALK rearrangement testing by fish analysis in non-small-cell lung cancer patients: Results of the first Italian external quality assurance scheme 158
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 158
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 158
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 157
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 157
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study 155
Second-line treatment of advanced non-small cell lung cancer 155
Totale 20.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 153.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.265 0 0 322 249 550 247 139 536 275 195 933 819
2022/20235.163 431 694 264 635 454 411 250 313 906 130 354 321
2023/20241.750 155 274 106 147 120 235 64 275 69 137 109 59
2024/20257.007 270 1.113 619 486 957 401 568 205 128 536 403 1.321
2025/202618.166 1.677 1.983 1.535 1.114 1.789 1.086 1.824 834 3.415 1.421 851 637
2026/20271.530 563 870 97 0 0 0 0 0 0 0 0 0
Totale 51.025